Quick Answer
INTEGRATED BIOPHARMA INC reported Cash And Cash Equivalents At Carrying Value of $3.62 million for the year ending 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +115.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from INTEGRATED BIOPHARMA INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), INTEGRATED BIOPHARMA INC's Cash And Cash Equivalents At Carrying Value has grown by 458.7%.
- Historical annual values: Fiscal year 2025: $3.62 million | Fiscal year 2024: $1.68 million | Fiscal year 2023: $1.32 million | Fiscal year 2022: $331.0 thousand | Fiscal year 2021: $210.0 thousand | Fiscal year 2020: $402.0 thousand | Fiscal year 2019: $475.0 thousand | Fiscal year 2018: $228.0 thousand | Fiscal year 2017: $132.0 thousand | Fiscal year 2016: $395.0 thousand | Fiscal year 2015: $71.0 thousand | Fiscal year 2014: $451.0 thousand | Fiscal year 2013: $55.0 thousand | Fiscal year 2012: $145.0 thousand | Fiscal year 2011: $725.0 thousand | Fiscal year 2010: $647.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: